Skip to main content

BUSCANDO UNA TERAPIA PARA LA EPILEPSIA MIOCLONICA PROGRESIVA DE LAFORA

SAF2014-54604-C3-1-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Regulación de la homeostasis del glucógeno: el papel de R6 y la enfermedad de Lafora

  • Rubio Villena, Carla
Tesis doctoral, 265 p., El glucógeno es la principal reserva de energía en nuestras células y es una molécula esencial para nuestro cerebro. Sin embargo, muchas cuestiones sobre el complejo metabolismo de este carbohidrato siguen por elucidar. Un paso clave en la regulación de la homeostasis del glucógeno es el llevado a cabo por la proteína fosfatasa de tipo 1, PP1. PP1 es capaz de estimular la síntesis de glucógeno mediante la desfosforilación de dos enzimas clave: la glucógeno sintasa (GS) y la glucógeno fosforilasa (GP). La fosfatasa necesita unirse a subunidades reguladoras para el reconocimiento de los diferentes sustratos. En el metabolismo del glucógeno, se han descrito hasta la fecha 7 de estas subunidades reguladoras, siendo R6 una de las más ubicuas y presente mayoritariamente en músculo esquelético, corazón y cerebro. En este trabajo hemos analizado la capacidad glucogénica de R6 en células de neuroblastoma de ratón. Se han estudiado además los diferentes dominios de unión presentes en R6 y su implicación en la regulación de la síntesis de glucógeno. Se ha caracterizado el motivo de unión de R6 a PP1 (R102VRF ) así como la zona de interacción con los diferentes sustratos: GS y GP (W267DNND). La unión a estos dos dominios de interacción ocurre de manera independiente, sin embargo, la pérdida de unión en cualquiera de ellos impide la estimulación de la síntesis de glucógeno producida por R6. Asimismo, hemos definido un nuevo dominio presente en R6 implicado en la unión a las proteínas 14-3-3 (RARS74LP). Esta unión media la regulación de la capacidad glucogénica de R6 ya que, cuando se impide la unión a la subunidad reguladora, la acumulación de glucógeno producida por R6 se ve exacerbada. Además, la unión de las proteínas 14-3-3 a R6 previene su degradación lisosomal, regulando por tanto la estabilidad de la proteína. Este mecanismo de regulación novedoso añadiría un grado más de complejidad a la homeostasis del metabolismo de glucógeno, mostrando una nueva manera de señalización. En este trabajo de tesis doctoral también hemos abordado la regulación del metabolismo del glucógeno en la enfermedad de Lafora (LD. OMIM 254780) y su relación con la subunidad reguladora R6. La enfermedad de Lafora es una enfermedad neurodegenerativa autosómica recesiva que conlleva epilepsia mioclónica progresiva y presenta un desenlace fatal. Debuta durante la adolescencia con ataques generalizados tónico clónicos, mioclonias, ausencias, desvanecimientos y alucinaciones visuales. La enfermedad progresa con demencia progresiva con apraxia, afasia y pérdidas visuales que llevan a los pacientes a un estado vegetativo y a la muerte, que tiene lugar generalmente a los 10 años desde la aparición de los primeros síntomas. Una marca de la enfermedad es la acumulación intracelular de “glucógeno insoluble”, los denominados cuerpos de Lafora. Dichas inclusiones aparecen en el citoplasma de múltiples tejidos entre los que se incluyen cerebro, riñón, piel, hígado y músculo esquelético y cardiaco., La composición de los cuerpos de Lafora se asemeja a la de un glucógeno pobremente ramificado, con características similares a un poliglucosano de plantas, la amilopectina, que le confieren la falta de solubilidad y por tanto, la aparición de inclusiones. Las mutaciones que causan la enfermedad de Lafora han sido identificadas en dos genes EPM2A y EPM2B, aunque hay evidencias de un tercer locus. EPM2A codifica para una fosfatasa dual, la laforina, con un dominio de unión a carbohidratos en la región N-terminal de la proteína. EPM2B codifica la proteína denominada malina, una E3 ubiquitin ligasa con un dominio RING en el extremo N-terminal y seis dominios NHL en la región C-terminal que están implicados en interacciones proteína-proteína. La presentación clínica en con mutaciones en uno u otro gen es muy similar, lo que sugiere que ambas proteínas operan en rutas fisiológicas similares. Aunque se conocen las dos principales proteínas que pueden causar la enfermedad, todavía esta muy poco claro cual es el papel fisiológico de ambas proteínas y como su ausencia o defecto pueden provocar efectos tan devastadores en el organismo que indefectiblemente llevan a la muerte de los pacientes afectados de esta enfermedad. El hecho de que uno de los determinantes histológicos que caracterizan la enfermedad de Lafora sea la acumulación de inclusiones intracelulares similares a glucógeno, sugiere que malina y laforina podrían estar involucradas en la regulación de la biosíntesis de glucógeno. Se ha descrito que laforina interacciona físicamente con malina reclutando substratos específicos para ser ubiquitinados por malina. Algunos de estos sustratos están implicados en la regulación de la biosíntesis de glucógeno, tal como la forma muscular de la glucógeno sintasa, la enzima desramificante de glucógeno y alguna subunidad reguladoras glucogénica de la fosfatasa de proteínas de tipo 1 (PP1) como R5/PTG. En esta tesis doctoral se ha descrito la relación funcional entre laforina y malina, las dos proteínas relacionadas con la enfermedad de Lafora, y R6. El complejo formado por laforina y malina es capaz de ubiquitinar a R6 y conducirla a degradación lisosomal. De esta manera, este complejo regula los niveles de proteína presente y la acumulación de glucógeno inducida por R6, controlando así la síntesis de glucógeno promovida por la subunidad reguladora. Dado que la enfermedad de Lafora es una enfermedad neurodegenerativa, hemos abordado por último el estudio del metabolismo de glucógeno en el cerebro., El metabolismo del glucógeno tiene un papel fundamental para el correcto funcionamiento de este órgano, en especial en la cooperación entre neuronas y astrocitos. En periodos de intensa actividad neuronal o durante episodios de hipoglucemia, el astrocito es capaz de generar lactato a partir de glucógeno, el cual puede ser usado por las neuronas adyacentes para continuar su normal funcionamiento. Por tanto, el glucógeno proveniente de los astrocitos provee de una neuroprotección contra la hipoglucemia o isquemia cerebral. En este trabajo hemos determinado que existe una alteración en el metabolismo del glucógeno en astrocitos provenientes de ratones modelo de la enfermedad (KO-malina y KO-laforina) de siete días de edad. En condiciones de crecimiento de alta glucosa, estos astrocitos primarios acumularon más glucógeno que los astrocitos control. Al contrario de lo que sucede con los cuerpos de Lafora, cuando los cultivos de astrocito primario fueron sometidos a ayuno de glucosa, observamos que este glucógeno acumulado se pudo degradar, presentando características similares a las de un glucógeno fisiológico. Además, se ha determinado que esta degradación ocurre mediante la acción de la glucógeno fosforilasa, mostrando que la maquinaría de degradación del glucógeno no está alterada en astrocitos primarios modelos de la enfermedad. Todos estos estudios además de ir encaminados a elucidar los mecanismos de patogenia de la enfermedad de Lafora, pueden ayudar a desvelar un posible tratamiento de la misma por modulación de las subunidades reguladoras glucogénicas de PP1, así como contribuir a una mayor comprensiónp del metabolismo del glucógeno., Para la realización de esta Tesis, Carla Rubio Villena ha disfrutado de una ayuda del Subprograma de Formación de Personal Investigador (FPI) (BES-2012-053264), Programa de Formación del Ministerio de Economía y Competitividad. El trabajo se ha llevado a cabo en el grupo U742 del CIBERER-Instituto de Salud Carlos III (IP, P. Sanz) enmarcado dentro de los siguientes proyectos de investigación: - Programa Nacional de Biomedicina. Proyecto SAF2011-27442. “Bases moleculares de la fisiopatología de la epilepsia mioclónica progresiva de tipo Lafora. Identificación de nuevos sustratos del complejo laforina-malina” Años 2012-2014. Investigador Principal: Dr. Pascual Sanz. Centro: Instituto de Biomedicina de Valencia (CSIC), Valencia. - Programa Nacional de Biomedicina. Proyecto SAF2014-54604-C3- 1-R. “Buscando una terapia para la epilepsia mioclónica progresiva de Lafora” Años 01/01/2015-31/12/2017. Investigador Principal: Dr. Pascual Sanz. Centro: Instituto de Biomedicina de Valencia (CSIC), Valencia. - Programa de investigación de excelencia Prometeo de la Generalitat Valenciana. Prometeo II/2014/029. “Genes, proteínas y rutas de señalización en enfermedades raras”. Años 2014-2018. Investigador Principal: Dr. Pascual Sanz. Investigadores asociados: Dr. Alberto Marina y Dr. Vicente Rubio. Centro: Instituto de Biomedicina de Valencia (CSIC), Valencia Durante la realización de esta tesis doctoral, la autora ha disfrutado de una Ayuda a la movilidad predoctoral para la realización de estancias breves en centros de I+D (dentro del Subprograma Estatal de Movilidad) referencia EEBB-I-15-09350 del Ministerio de Economía y Competitividad., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Degradation of altered mitochondria by autophagy is impaired in Lafora disease

  • Lahuerta, Marcos
  • Aguado, Carmen
  • Sánchez-Martín, Pablo
  • Sanz, Pascual
  • Knecht, Erwin
20 páginas, 13 figuras, Lafora disease (LD) is a fatal neurodegenerative disorder caused mostly by mutations in either of two genes encoding laforin and malin. LD is characterized by accumulation of a poorly branched form of glycogen in the cytoplasm of neurons and other cells. We previously reported dysfunctional mitochondria in different LD models. Now, using mitochondrial uncouplers and respiratory chain inhibitors, we have investigated with human fibroblasts a possible alteration in the selective degradation of damaged mitochondria (mitophagy) in LD. By flow cytometry of MitoTracker-labelled cells and measuring the levels of various mitochondrial proteins by western blot, we found in LD fibroblasts a partial impairment in the increased mitochondrial degradation produced by these treatments. In addition, colocalization of mitochondrial and lysosomal markers decreased in LD fibroblasts. All these results are consistent with a partial impairment in the induced autophagic degradation of dysfunctional mitochondria in LD fibroblasts. However, canonical recruitment of Parkin to mitochondria under these conditions remained unaffected in LD fibroblasts, and also in SH-SY5Y cells after malin and laforin overexpression. Neither mitochondrial localization nor protein levels of Bcl-2-like protein 13, another component of the mitophagic machinery that operates under these conditions, were affected in LD fibroblasts. In contrast, although these treatments raised autophagy in both control and LD fibroblasts, this enhanced autophagy was clearly lower in the latter cells. Therefore, the autophagic degradation of altered mitochondria is impaired in LD, which is due to a partial defect in the autophagic response and not in the canonical mitophagy signalling pathways., This work was supported by grants SAF2014-54604-C3-1-R and SAF2014- 54604-C3-2-R from the Spanish Ministry of Economy and Competitiveness, a grant from Generalitat Valenciana (PrometeoII/2014/029) and a grant from the National Institute of Health P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI). P.S-M and M.L. holds a FPU and FPI fellowship, respectively, from the Spanish Ministry of Education, Culture and Sports., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Astrocytes: new players in progressive myoclonus epilepsy of Lafora type

  • Rubio-Villena, Carla
  • Viana, Rosa
  • Bonet, Jose
  • García-Gimeno, María Adelaida
  • Casado, Marta
  • Heredia, Miguel
  • Sanz, Pascual
11 páginas, 7 figuras. This is a pre-copyedited, author-produced version of an article accepted for publication in Human Molecular Genetics following peer review. The version of record Rubio-Villena C., Viana R., Bonet J., Garcia-Gimeno M.A., Casado M., Heredia M.,Sanz P. (2018). Astrocytes: new players in progressive myoclonus epilepsy of Lafora type. Hum Mol Genet 27(7): 1290-1300, is available online at: http://dx.doi.org/10.1093/hmg/ddy044, Lafora disease (LD) is a fatal form of progressive myoclonus epilepsy characterized by the accumulation of insoluble poorly branched glycogen-like inclusions named Lafora bodies (LBs) in the brain and peripheral tissues. In the brain, since its first discovery in 1911, it was assumed that these glycogen inclusions were only present in affected neurons. Mouse models of LD have been obtained recently, and we and others have been able to report the accumulation of glycogen inclusions in the brain of LD animals, what recapitulates the hallmark of the disease. In this work we present evidence indicating that, although in mouse models of LD glycogen inclusions co-localize with neurons, as originally established, most of them co-localize with astrocytic markers such as glial fibrillary acidic protein (GFAP) and glutamine synthase. In addition, we have observed that primary cultures of astrocytes from LD mouse models accumulate higher levels of glycogen than controls. These results suggest that astrocytes may play a crucial role in the pathophysiology of Lafora disease, as the accumulation of glycogen inclusions in these cells may affect their regular functionality leading them to a possible neuronal dysfunction., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2014-54604-C3-1-R, a grant from Generalitat Valenciana (PrometeoII/2014/029), a grant form Fundación Ramón Areces (XVIII Concurso Nacional Ayudas Investigacion Ciencias Vida y Materia) and a grant from the National Institute of Health (NIH-NINDS) P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to PS and grants SAF2016-75004-R and Contribution to COST Action CA15203 MITOEAGLE to MC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A novel EPM2A mutation yields a slow progression form of Lafora disease

  • García-Gimeno, María Adelaida
  • Rodilla-Ramirez, Pilar Natalia
  • Viana, Rosa
  • Salas-Puig, Xavier
  • Brewer, M. Kathryn
  • Gentry, Matthew S.
  • Sanz, Pascual
9 páginas, 4 figuras. contiene 2 figuras en material suplementario, Lafora disease (LD, OMIM 254780) is a rare disorder characterized by epilepsy and neurodegeneration leading patients to a vegetative state and death, usually within the first decade from the onset of the first symptoms. In the vast majority of cases LD is related to mutations in either the EPM2A gene (encoding the glucan phosphatase laforin) or the EPM2B gene (encoding the E3-ubiquitin ligase malin). In this work, we characterize the mutations present in the EPM2A gene in a patient displaying a slow progression form of the disease. The patient is compound heterozygous with Y112X and N163D mutations in the corresponding alleles. In primary fibroblasts obtained from the patient, we analyzed the expression of the mutated alleles by quantitative real time PCR and found slightly lower levels of expression of the EPM2A gene respect to control cells. However, by Western blotting we were unable to detect endogenous levels of the protein in crude extracts from patient fibroblasts. The Y112X mutation would render a truncated protein lacking the phosphatase domain and likely degraded. Since minute amounts of laforin-N163D might still play a role in cell physiology, we analyzed the biochemical characteristics of the N163D mutation. We found that recombinant laforin N163D protein was as stable as wild type and exhibited near wild type phosphatase activity towards biologically relevant substrates. On the contrary, it showed a severe impairment in the interaction profile with previously identified laforin binding partners. These results lead us to conclude that the slow progression of the disease present in this patient could be either due to the specific biochemical properties of laforin N163D or to the presence of alternative genetic modifying factors separate from pathogenicity., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2014-54604-C3-1-R and a grant from Generalitat Valenciana (PrometeoII/2014/029); and National Institute of Health grants R01NS070899 and P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

AMPK Protein Interaction Analyses by Yeast Two-Hybrid

  • Sanz, Pascual
  • Viana, Rosa
  • García-Gimeno, María Adelaida
This is a post-peer-review, pre-copyedit version of an article published in Methods in Molecular Biology. The final authenticated version is available online at: http://dx.doi.org/10.1007/978-1-4939-7598-3_9 (15 páginas, 5 figuras), Mammalian AMP-activated protein kinase (AMPK) is a Ser/Thr protein kinase that acts as a crucial energy sensor in the cell. Since AMPK plays a key role in a multitude of different pathways in the cell, major efforts have been concentrated to elucidate its signaling network, mainly by the identification of AMPK downstream targets. In this chapter we describe a yeast two-hybrid method for the direct evaluation of the interaction between an AMPK subunit and putative substrates., This study was supported by grants from the Spanish Ministry of Education and Science (SAF2014-54604-C3-1-R) and Generalitat Valenciana (PrometeoII/2014/029) to P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In vivo glutamate clearance defects in a mouse model of Lafora disease

  • Muñoz-Ballester, Carmen
  • Santana, N.
  • Pérez-Jiménez, Eva
  • Viana, Rosa
  • Artigas, Francesc
  • Sanz, Pascual
9 páginas, 5 figuras, 1 tabla, Lafora disease (LD) is a fatal rare neurodegenerative disorder characterized by epilepsy, neurodegeneration and insoluble polyglucosan accumulation in brain and other peripheral tissues. Although in the last two decades we have increased our knowledge on the molecular basis underlying the pathophysiology of LD, only a small part of the research in LD has paid attention to the mechanisms triggering one of the most lethal features of the disease: epilepsy. Recent studies in our laboratory suggested that a dysfunction in the activity of the mouse astrocytic glutamate transporter 1 (GLT-1) could contribute to epilepsy in LD. In this work, we present new in vivo evidence of a GLT-1 dysfunction, contributing to increased levels of extracellular glutamate in the hippocampus of a mouse model of Lafora disease (Epm2b-/-, lacking the E3-ubiquitin ligase malin). According to our results, Epm2b-/- mice showed an increased neuronal activity, as assessed by c-fos expression, in the hippocampus, an area directly correlated to epileptogenesis. This brain area presented lesser ability to remove synaptic glutamate after local GLT-1 blockade with dihydrokainate (DHK), in comparison to Epm2b+/+ animals, suggesting that these animals have a compromised glutamate clearance when a challenging condition was presented. These results correlate with a hippocampal upregulation of the minor isoform of the Glt-1 gene, named Glt-1b, which has been associated with compensatory mechanisms activated in response to neuronal stress. In conclusion, the hippocampus of Epm2b-/- mice presents an in vivo impairment in glutamate uptake which could contribute to epileptogenesis., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2014-54604-C3-1-R, SAF2017-83151-R (to P.S.) and SAF2015-68346-P (to F.A.), co-funded by the European Regional Development Fund “A way to build Europe” (to F.A.), a grant from Fundación Ramón Areces (CIVP18A3935) and a grant from the National Institute of Health (NIH-NINDS) P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S. The Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and de Enfermedades Raras (CIBERER) are also acknowledged for financial support. We also thank Letizia Campa and Verónica Paz for their outstanding technical assistance. C.M.-B. holds a FPU fellowship from the Spanish Ministry of Education, Culture and Sports., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Regulation of the autophagic PI3KC3 complex by laforin/malin E3-ubiquitin ligase, two proteins involved in Lafora disease

  • Sánchez-Martín, Pablo
  • Lahuerta, Marcos
  • Viana, Rosa
  • Knecht, Erwin
  • Sanz, Pascual
15 páginas, 10 figuras. The Transparency document associated this article can be found, in online version. Appendix A. Supplementary data: https://doi.org/10.1016/j.bbamcr.2019.118613., Lafora progressive myoclonus epilepsy is a fatal rare neurodegenerative disorder characterized by the accumulation of insoluble abnormal glycogen deposits in the brain and peripheral tissues. Mutations in at least two genes are responsible for the disease: EPM2A, encoding the glucan phosphatase laforin, and EPM2B, encoding the RING-type E3-ubiquitin ligase malin. Both laforin and malin form a functional complex in which laforin recruits the substrates to be ubiquitinated by malin. We and others have described that, in cellular and animal models of this disease, there is an autophagy impairment which leads to the accumulation of dysfunctional mitochondria. In addition, we established that the autophagic defect occurred at the initial steps of autophagosome formation. In this work, we present evidence that in cellular models of the disease there is a decrease in the amount of phosphatidylinositol-3P. This is probably due to defective regulation of the autophagic PI3KC3 complex, in the absence of a functional laforin/malin complex. In fact, we demonstrate that the laforin/malin complex interacts physically and co-localizes intracellularly with core components of the PI3KC3 complex (Beclin1, Vps34 and Vps15), and that this interaction is specific and results in the polyubiquitination of these proteins. In addition, the laforin/malin complex is also able to polyubiquitinate ATG14L and UVRAG. Finally, we show that overexpression of the laforin/malin complex increases PI3KC3 activity. All these results suggest a new role of the laforin/malin complex in the activation of autophagy via regulation of the PI3KC3 complex and explain the defect in autophagy described in Lafora disease., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2014-54604-C3-1-R and SAF2017- 83151-R, a grant from Fundación Ramón Areces (CIVP18A3935) and a grant from the National Institutes of Health (NIH-NINDS) P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to PS. We also acknowledge a grant from the Spanish Ministry of Economy and Competitiveness SAF2014-54604-C3-2-R to EK., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Reactive Glia-Derived Neuroinflammation: a Novel Hallmark in Lafora Progressive Myoclonus Epilepsy That Progresses with Age

  • Lahuerta, Marcos
  • Gonzalez, Daymé
  • Aguado, Carmen
  • Fathinajafabadi, Alihamze
  • García-Giménez, José Luis
  • Moreno-Estellés, Mireia
  • Romá-Mateo, Carlos
  • Knecht, Erwin
  • Pallardó, Federico V.
  • Sanz, Pascual
15 páginas, 7 figuras, 3 tablas. Contiene en material suplementario adjunto: 2 figuras y 8 tablas., Lafora disease (LD) is a rare, fatal form of progressive myoclonus epilepsy. The molecular basis of this devastating disease is still poorly understood, and no treatment is available yet, which leads to the death of the patients around 10 years from the onset of the first symptoms. The hallmark of LD is the accumulation of insoluble glycogen-like inclusions in the brain and peripheral tissues, as a consequence of altered glycogen homeostasis. In addition, other determinants in the pathophysiology of LD have been suggested, such as proteostasis impairment, with reduction in autophagy, and oxidative stress, among others. In order to gain a general view of the genes involved in the pathophysiology of LD, in this work, we have performed RNA-Seq transcriptome analyses of whole-brain tissue from two independent mouse models of the disease, namely Epm2a-/- and Epm2b-/- mice, at different times of age. Our results provide strong evidence for three major facts: first, in both models of LD, we found a common set of upregulated genes, most of them encoding mediators of inflammatory response; second, there was a progression with the age in the appearance of these inflammatory markers, starting at 3 months of age; and third, reactive glia was responsible for the expression of these inflammatory genes. These results clearly indicate that neuroinflammation is one of the most important traits to be considered in order to fully understand the pathophysiology of LD, and define reactive glia as novel therapeutic targets in the disease., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2014-54604-C3-1-R and SAF2017-83151-R, a grant from Fundación Ramón Areces (CIVP18A3935) and a grant from the National Institute of Health (NIH-NINDS) P01NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to PS. We also acknowledge a grant from the Spanish Ministry of Economy and Competitiveness SAF2014-54604-C3-2-R to EK and a grant from Generalitat Valenciana Prometeo2018/135 to PS and FVP., Peer reviewed